0
Original Contribution |

Substantia Nigra Volume Loss Before Basal Forebrain Degeneration in Early Parkinson Disease

David A. Ziegler, PhD; Julien S. Wonderlick, MD; Paymon Ashourian, PhD; Leslie A. Hansen, BS; Jeremy C. Young, BS; Alex J. Murphy, BS; Cecily K. Koppuzha, BS; John H. Growdon, MD; Suzanne Corkin, PhD
JAMA Neurol. 2013;70(2):241-247. doi:10.1001/jamaneurol.2013.597.
Text Size: A A A
Published online

Objective  To test the hypothesis that degeneration of the substantia nigra pars compacta (SNc) precedes that of the cholinergic basal forebrain (BF) in Parkinson disease (PD) using new multispectral structural magnetic resonance (MR) imaging tools to measure the volumes of the SNc and BF.

Design  Matched case-control study.

Setting  The Athinoula A. Martinos Imaging Center at the McGovern Institute for Brain Research, Massachusetts Institute of Technology (MIT), and the Massachusetts General Hospital/MIT Morris Udall Center of Excellence in Parkinson Disease Research.

Patients  Participants included 29 patients with PD (Hoehn and Yahr [H&Y] stages 1-3) and 27 matched healthy control subjects.

Main Outcome Measures  We acquired multiecho T1-weighted, multiecho proton density, T2-weighted, and T2-weighted fluid-attenuated inversion recovery (FLAIR) sequences from each participant. For the SNc, we created a weighted mean of the multiple echoes, yielding a single volume with a high ratio of contrast to noise. We visualized the BF using T2-weighted FLAIR images. For each participant, we manually labeled the 2 structures and calculated their volumes.

Results  Relative to the controls, 13 patients with H&Y stage 1 PD had significantly decreased SNc volumes. Sixteen patients with H&Y stage 2 or 3 PD showed little additional volume loss. In contrast, the BF volume loss occurred later in the disease, with a significant decrease apparent in patients having H&Y stage 2 or 3 PD compared with the controls and the patients having H&Y stage 1 PD. The latter group did not differ significantly from the controls.

Conclusion  Our results support the proposed neuropathological trajectory in PD and establish novel multispectral methods as MR imaging biomarkers for tracking the degeneration of the SNc and BF.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Grahic Jump Location

Figure 1. Control subject. A and B, Representative axial (A) and sagittal (B) views of the midbrain of a control subject's multispectral weighted mean. The red arrows in A and B indicate the substantia nigra. C, Shown are the substantia nigra pars compacta (SNc), substantia nigra pars reticulata (SNr), red nucleus (RN), and cerebral peduncles (CP). D, Example of the same control subject's manually delimited label of the SNc (green).

Place holder to copy figure label and caption
Grahic Jump Location

Figure 2. Coronal images from a control subject showing the basal forebrain at the level of the anterior commissure. A, T2-weighted image. B, T2–fluid-attenuated inversion recovery (FLAIR) weighted image clearly demonstrates the improved contrast for both the superior and inferior boundaries in T2-FLAIR weighted images. The red arrows in A and B indicate the basal forebrain. C, T2-FLAIR weighted image with a manually delimited label of the basal forebrain (red).

Place holder to copy figure label and caption
Grahic Jump Location

Figure 3. The mean volumes of the substantia nigra pars compacta (A) and basal forebrain (B) for the left and right hemispheres. Shown are values for control subjects, patients with Hoehn and Yahr stage 1 Parkinson disease (H&Y 1), and patients with Hoehn and Yahr stages 2 and 3 Parkinson disease (H&Y 2-3). Bars are means (SEs). *Denotes P < .05; † denotes P < .10.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 4. Multispectral weighted means showing the substantia nigra pars compacta (red arrows) in sagittal and axial views. A, Healthy young adult (21-year-old female). B, Healthy older control subject (69-year-old female). C, Age-matched and sex-matched patient with Hoehn and Yahr stage 2 Parkinson disease (H&Y 2) (69-year-old female). Signal loss is readily apparent in the Parkinson disease brain (yellow arrows).

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com